Page 16 - Read Online

J Cancer Metastasis Treat 2019;5:5 I http://dx.doi.org/10.20517/2394-4722.2018.108 Page 11 of 27

chemotherapy. Further investigation and treatment optimization is required in order to demonstrate a
potential effectiveness of SS-31 in the chemotherapy-treated tumor-bearing mice.

15. L1CAM gene overexpression is associated with platinum-resistance in high-risk
endometrial carcinoma

1,2
1,2
1
1
2,3
Eliana Bignotti , Antonella Ravaggi , Martina Ratti , Germana Tognon , Paola Todeschini ,
3
3
2,3
Laura Zanotti , Enrico Sartori , Franco Odicino , Chiara Romani 4
1 U.O. Obstetrics and Gynecology, ASST Spedali Civili di Brescia, Brescia 25123, Italy.
2 IMM “A. Nocivelli”, ASST Spedali Civili di Brescia, Brescia 25123, Italy.
3 Division of Obstetrics and Gynecology, University of Brescia, Brescia 25121, Italy.
4 Molecular and Translational Medicine Department, University of Brescia, Brescia 25121, Italy.
Introduction: L1 cell adhesion molecule (L1CAM) expression has been reported associated with high-grade
disease and non-endometrioid histology, as well as poor prognosis, in endometrial carcinoma (EC). These
high-risk EC types have frequently already spread outside the uterus when diagnosed and, after an extensive
surgery, are often treated with chemo and radiation therapy. We hypothesized that L1CAM gene expression
could discriminate, among poor outcome EC patients, those who do and who do not respond to adjuvant
platinum-based chemotherapy.

Experimental model: Using an efficient multiplex qRT-PCR, we test L1CAM mRNA expression on 117 EC
and 16 normal endometrial (NE) flash-frozen tissues, with HPRT1 and PPIA as reference genes.

Results: L1CAM mRNA was significantly overexpressed in EC compared to NE tissues (P = 0.02),
significantly upregulated in G3 vs. G1-2 ECs (P < 0.001) and in non-endometrioid vs. endometrioid ECs
(P < 0.001). Our analysis showed no difference in L1CAM expression of stage I-II vs. stage III-IV ECs (P
= 0.5). Of the initial 117 EC patients, 47 received chemotherapy on adjuvant setting and were classified as
platinum-sensitive and platinum-resistant patients, based on PFI > 12 months and < 6 months, respectively.
L1CAM gene was significantly overexpressed in resistant vs sensitive EC (P = 0.001). Moreover, by means of
a multivariate logistic regression model, we found L1CAM gene overexpression as an independent indicator
of the probability to harbor a platinum-resistant EC (P = 0.047, OR = 3.5). In addition, univariate and
multivariate survival analysis showed L1CAM gene upregulation associated with poor outcome, in terms of
progression-free survival and disease-specific survival.

Conclusion: Our results suggest L1CAM gene expression as a potential prognostic marker and a predictive
biomarker of platinum-response in high-risk EC patients.

16. Resveratrol counteracts ovarian cancer cell migration stimulated by interleukin-6 by
limiting glucose uptake

1
1
1
1
1
Chiara Vidoni , Alessandra Ferraresi , Letizia Vallino , Andrea Esposito , Eleonora Secomandi ,
2
Danny N. Dhanasekaran , Ciro Isidoro 1
1 Laboratory of Molecular Pathology and Nanobioimaging, Department of Health Sciences, Università del
Piemonte Orientale “A. Avogadro”, Via Solaroli 17, Novara 28100, Italy.
2 Stephenson Cancer Center and Department of Cell Biology, The University of Oklahoma Health Sciences
Center, Oklahoma City, OK 73104, USA.